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J. K. MICKELSON, P. J. SIMPSON AND B. R. LUCCHESI. Antiplatelet Monoclonal F(ab’), Antibody Directed 
Against the Platelet GPIIb/IIIa Receptor Complex Prevents Coronary Artery Thrombosis in the Canine Heart. 
Journal of Molecular end Cellular Cardiology (1989) 21, 3933405. Interactions between platelets with injured vascu- 
lar endothelium contribute to thrombotic occlusion. A murine monoclonal antibody [7E3 F(ab’),] to the platr- 
let GPIIb/IIIa receptor complex was used to inhibit platelet aggregation in an experimental model of coronary 
artery thrombosis. Prevention of thrombotic occlusion by 7E3 F(ab’), (0.8 mg/kg bolus i.v.) was studied in dogs 
with direct current induced intimal injury (100 PA for 5 h) and critical stenosis of the left circumflex coronary 
artery (LCCA). Baseline LCCA blood flow (CBF) was similar in 7E3 F(ab’), and control groups, but decreased 
in the controls [24 + 2 ml/min to 0 + 0 ml/min, n = 13 (mean ~s.E.M.)] due to thrombotic occlusion in each 
case (time to thrombosis 136 f 15 min). In the group treated with 7E3 F(ab’),, CBF did not change signifi- 
cantly (27 + 3 ml/min to 22 k 3 ml/min, a = 6) and thrombotic occlusion did not occur during the 5-h observa- 
tion period in which intimal injury was produced in the LCCA (P < 0.001). Oscillations in CBF preceded 
thrombosis in the control group, but did not occur with 7E3 F(ab’), treatment (2.2 + 0.7 vs. 0 + 0, P < 0.05). 
The thrombus mass recovered from the LCCA 30 min after occlusion was 8.8 + 1.3 mg in the controls com- 
pared to 2.2 & 1.2 mg determined 5 h after administration of 7E3 F(ab’)s (P < 0.05). When studied ex uivo, 
before the administration of the test agents, platelets from both groups of dogs aggregated in response to ADP 
and arachidonic acid. However, after treatment, the ex viva aggregation of platelets from 7E3 F(ab’), animals 
was inhibited whereas platelets from the control animals continued to aggregate ex tiuo throughout the period of 
the experimental protocol (P < 0.05). The labeling of platelets with “‘iridium showed accumulation of radio- 
activity within the thrombus and upon the vascular endothelium which was less in 7E3 F(ab’), treated dogs as 
compared to the control group (P < 0.05). The murine monoclonal antibody 7E3 F(ab’)s did not affect hemo- 
dynamic values or the circulating platelet count during the experimental protocol. In conclusion, antibody to 
platelet GPIIb/IIIa receptors: (1) prevented thrombotic LCCA occlusion, (2) inhibited ex viuo platelet aggre- 
gation, (3) minimized platelet deposition on injured vascular endothelium and within formed thrombi. and (4) 
stabilized CBF during 5 h ofcontinuous direct currrent induced intimal injury of the LCCA. 
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introduction 
The interaction of blood platelets with the 
endothelial surface of injured blood vessels as 
well as with other platelets is associated with 
the development of serious thromboembolic 
disorders and is a major factor in coronary 
artery thrombosis and reocclusion after suc- 
cessful angioplasty and or thrombolytic 
therapy (DeWood et al., 1980; Harrison et al., 
1984: Gold et al., 1986; Bates et al., 1987; 
Golino et al., 1988). Recent knowledge 
regarding platelet surface receptors suggest 
that they participate in both platelet-- 
endothelial cell adhesion and platelet-platelet 
interaction leading to aggregation 
(Sakariassen et al., 1986). Platelet adhesion, 
consisting of a single layer of cells, at the site of 
vessel injury is essential for hemostasis and 
offers a minimal threat to the formation of an 
occlusive thrombus. Conversely, intravascular 
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platelet aggregation involves the formation of 
a platelet-fibrin mass which has the potential 
to embolize or to form an obstructive lesion. 
The agonists that are thought to initiate plate- 
let aggregation in z&o (adenosine, ADP, epi- 
nephrine, collagen and thrombin) are 
dependent upon the binding of fibrinogen or 
other ligands to the glycoprotein IIb/IIIa 
(GPIIb/IIIa) receptor (Coller et al., 1983; 
Coller, 1985 ; Coller and Scudder, 1985). The 
important role of the GPIIb/IIIa receptor has 
been demonstrated by several studies describ- 
ing monoclonal antibodies that bind specifi- 
cally with the receptor complex. The 
inhibition of the GPIIb/IIIa receptor pre- 
vents the binding of fibrinogen and other 
adhesive glycoproteins to the platelet. The 
recent development of monoclonal antibodies 
directed against specific epitopes on the 
GPIIb/IIIa complex offers an opportunity to 
explore the use of specific antibodies in the 
prevention of thrombosis due to in uivo platelet 
aggregation in response to vessel injury. There 
are in vitro and in vivo data to demonstrate that 
7E3 F(ab’), fragments of a monoclonal anti- 
platelet antibody can inhibit platelet function 
without producing hemorrhage or significant 
thrombocytopenia (Coller and Scudder, 
1985). 
In the present study we explored the anti- 
thrombotic efficacy of a murine monoclonal 
antibody [7E3 F(ab’),] that binds to the 
platelet glycoprotein IIb/IIIa receptor. The 
results of this study indicate that inhibition of 
the GPIIb/IIIa receptor complex with a 
monoclonal antibody results in an alteration 
of the platelet response to vascular wall injury 
thereby preventing the formation of occlusive 
coronary artery thrombosis in the experimen- 
tal animal. The clinical application of this 
approach may provide an important adjunc- 
tive therapeutic intervention directed against 
thrombotic reocclusion after successful coro- 
nary angioplasty and/or thrombolytic 
therapy. 
Methods 
Surgical preparation and instrumentation 
Male mongrel dogs, 14 to 20 kg, were selected 
based on the ability of their platelets to aggre- 
gate in response to arachidonic acid and 
adenosine diphosphate (ADP). The animals 
were anesthetized with sodium pentobarbital 
(30 mg/kg, i.v.), intubated and ventilated on 
room air with positive pressure using a 
Harvard respirator (Harvard Apparatus, S. 
Natick, MA) at a volume 30 ml/kg and a fre- 
quency of 12 breaths/min. Surgery was per- 
formed under aseptic conditions beginning 
with the placement of cannulas into the left 
carotid artery and jugular vein for monitoring 
arterial blood pressure (Statham P23 pressure 
transducer, Gould Inc., Cardiovascular Pro- 
ducts, Oxnard, CA) and administering intra- 
venous fluids. The heart was exposed via a left 
thoracotomy through the 5th intercostal 
space. A 2-cm segment of the left circumflex 
coronary artery (LCCA) was isolated from 
surrounding tissue by blunt dissection. The 
artery was instrumented from proximal to 
distal with an electromagnetic flow probe 
(Model 50 1, Carolina Medical Electronics, 
Inc., King, NC), intracoronary electrode and 
screw occluder (Fig. 1). The intracoronary 
electrode was constructed from a 25-gauge 
hypodermic needle tip attached to a 30-gauge 
Teflon-insulated silver-coated copper wire. 
The mechanical occluder was constructed of 
stainless steel in a C shape with a Teflon screw 
(2 mm diameter), which could be adjusted to 
control vessel circumference. The external 
screw occluder was adjusted to decrease the 
reactive hyperemic flow (10 s occlusion) by 50 
to 70% without affecting basal coronary 
blood flow. A monopolar epicardial electrode 
was sutured to the surface of the ventricle in 
the region of LCCA distribution to monitor 
ischemic changes. The left atrium was cannu- 
lated with polyethylene tubing for adminis- 
tration of “‘iridium labeled platelets, platelet 
antibody or saline, and Super Imperse Blue 
dye. Continuous recordings of blood pressure, 
limb lead II ECG, epicardial electrogram, 
and mean and phasic LCCA blood flow were 
obtained on a Model 7 polygraph (Grass 
Instrument Co., Quincy, MA). 
Protocol 
Thirty minutes after the surgical preparation 
was completed, the experimental protocol was 
initiated. Platelets labeled with “‘iridium 
were administered and 15 min later the 
animals were given either platelet antibody or 
an equivalent volume of vehicle (normal 

















FIGURE 1. Instrumentation of the left circumflex coronary artery. After isolation of the circumflex coronary artery. 
it was instrumented from proximal to distal with an electromagnetic flow probe, insertion of the intracoronary anodal 
stimulation electrode, and a mechanical constrictor device for applying an external stenosis to the vessel. The schematic 
diagram in the lower portion of the figure illustrates the method used to quantitate the accretion of “‘iridium labeled 
platelets in the thrombus mass and to calculate the ratio among comparable segments of the left circumflex coronar) 
artery and the left anterior descending coronary artery. 
saline) via the left atrium. Finally, 15 min 
after administration of platelet antibody or 
saline, a 100 PA continuous anodal direct 
current stimulation was appIied to the intimal 
surface of the LCCA. The anodal direct 
current was delivered from a 9 V nickel- 
cadmium battery. The anode of the battery 
was in series with a 250000 R potentiometer 
and the intraluminal coronary artery elec- 
trode. The electric circuit was completed by 
placing the cathode in a subcutaneous site. 
Prior to occlusion of the artery, spontaneous 
oscillations in flow occur which have been 
attributed to either altered vasomotor tone 
“vasospasm”, or formation and dislodgement 
of partially occlusive platelet thrombi, or 
perhaps a combination of these phenomenon. 
The number of oscillations preceding the final 
occlusive event was recorded. 
Each experiment was considered complete 
30 min after persistent thrombotic coronary 
artery occlusion developed or 5 h after initi- 
ation of electrical stimulation, whichever 
occurred first. At the conclusion of the experi- 
mental procedure, 10 ml of Super Imperse 
Blue dye was injected into the left atrium 
while occluding the LCCA proximal to the 
area of insertion of the stimulating electrode. 
In this manner the area subserved by thr 
LCCA, based on the fact that no dye can 
enter this distribution, was determined in uiuo. 
The heart was fibrillated electrically 10 s later 
and removed quickly. The LCCA was dis- 
sected free as far as possible and opened longi- 
tudinally; the position of the implanted 
anodal electrode was verified and the 
thrombus was removed and weighed. In selec- 
ted experiments the thrombus was left in situ 
and the vessel was placed in an appropriate 
fixative and processed for scanning electron 
microscopy. 
The heart was cut from apex to base in 1 .O 
cm thick sections which were incubated in tri- 
phenyltetrazolium chloride (TPT) for 5 min 
at 37°C. The transverse sections were weighed 
and traced onto clear plastic sheets: the area 
stained by Super Imperse Blue dye was the 
non-risk region (not in the L,CCA 
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distribution), the red stained viable tissue was 
the risk region (LCCA distribution). Myo- 
cardial tissue in the distribution of the LCCA 
which did not react with tetrazolium and 
form a red formazan precipitate was con- 
sidered to be irreversibly injured. The various 
demarcated areas were quantitated with an 
Apple IIe microprocessor and the data were 
expressed as a percent of the total left ven- 
tricular weight. 
Platelet studies 
Platelet counts and ex viva aggregation studies 
were performed at baseline, 1 h and 5 h after 
treatment was given. The platelet count was 
determined with a Haema Count MK-4/HC 
platelet counting system. Platelet rich plasma 
(PRP) was prepared from venous blood, using 
3.2% sodium citrate as the anticoagulant and 
the supernate was harvested after centrifu- 
gation at 1000 r/min for 5 min ( 140 X g). 
Platelet poor plasma (PPP) was prepared by 
centrifuging the remaining blood at 
12 000 x g for 10 min and discarding the 
cells. The platelet count of the PRP was deter- 
mined and then diluted with PPP to achieve a 
cell count of 200000/mm3. Platelet aggre- 
gation was determined by established spec- 
trophotometric methods using a four-channel 
aggregometer (BioData-PAP-4) and record- 
ing the increase in light transmission through 
a stirred suspension of PRP maintained at 
37°C (Mills and Roberts, 1967). Aggregation 
was induced by: ADP 5 jLM, ADP 2.5 PM, ara- 
chidonic acid (AA) 0.65 mM or 0.325 mM. Epi- 
nephrine (550 nM) was used to prime the 
platelets before stimulation with AA. In vitro 
studies were performed with 7E3 F(ab’)z at 
concentrations of 10, 20 and 40 pg/ml to 
compare AA induced aggregation with the 
above mentioned ex vivo studies and to test col- 
lagen as an agonist. Aggregation was initiated 
by the addition of collagen ( 1 : 10 and 1 : 80 
dilution of Ethicon Collagen Dispersion-TD 
150) to PRP. Values were expressed as per- 
centage of light transmission standardized to 
PRP and PPP samples yielding 0% and 100% 
light transmission, respectively. 
Radiolabeling of platelets with Ill-indium oxine 
Before the thoracotomy, blood (43.5 ml) was 
withdrawn from the internal jugular cannula 
into a plastic syringe containing 7.5 ml of 
3.2% sodium citrate. The blood was centri- 
fuged at 220 x g and the supernatant PRP 
was removed and the platelets were washed 
with acidified (pH 6.5) calcium-free Tyrode’s 
buffer containing 0.3 mM EDTA and 0.35% 
bovine serum albumin as described previously 
(Thakur et al., 1976). The washed platelets 
were resuspended gently in 10 ml of Tyrode’s 
buffer and incubated for 15 min at room tem- 
perature with 500 &i ‘“iridium oxine 
(Diagnostic Isotopes, Inc., NJ). The PRP was 
centrifuged at 1000 x g for 10 min to remove 
radioactivity not bound to the platelets. The 
labeled platelets were resuspended in 5 ml of 
buffer and injected via the left atria1 cannula. 
Samples were taken during the procedure so 
that labeling efficiency could be determined 
(Romson et al., 1982). 
Fifteen minutes after injecting the 
“‘indium oxine labeled platelets, samples of 
blood were taken from the internal jugular 
cannula to determine recovery of the radio- 
label. Blood was collected 1 h and 5 h after 
treatment with either the platelet antibody or 
normal saline for determining recovery of the 
radiolabel (Porter-Fink and Eckhauser, 
1981). I f  the artery had occluded, the sample 
was not obtained. 
In the studies conducted with “‘iridium 
oxine labeled platelets, the distribution of the 
radiolabel was determined in the thrombus, 
LCCA and left anterior descending coronary 
artery (LAD). A 2 to 3 cm segment of the 
LAD was dissected free and cut into three seg- 
ments (proximal, middle and distal) which 
served as the reference for radiolabeled counts 
(Fig. I). In the LCCA the middle segment 
was the one containing the stimulation elec- 
trode. The weighed samples (vessel and 
thrombus) were counted in a Packard 5320 
gamma spectrometer. Radioactivity in each 
sample was expressed as counts/min/g of 
tissue. For comparison purposes, in each 
experiment radioactivity ratios were calcu- 
lated for similar segments, i.e. mid LCCA/mid 
LAD. 
Antibody administration 
Dogs were randomized to receive a single 
bolus of either normal saline (0.4 ml/kg) or 
monoclonal platelet antibody 7E3 F(ab’), 
(0.8 mg/kg). When ” ‘iridium labeled plate- 
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lets were used, the antibody or vehicle treat- 
ment was given 15 min after the labeled 
platelets were injected, but 15 min before the 
current was applied to the intracoronary elec- 
trode. The antibody was provided by Cento- 
car, Inc. (Malvern, PA) as a sterile, pyrogen 
free solution. 
Detection of residual monoclonalplatelet antibody 
7E3 F(ab’)2 
To determine the characteristics of antibody 
uptake by platelets, samples of plasma were 
analyzed for the presence of residual antibody 
at baseline, 1 h and 5 h after administration. 
Antibody was detected by indirect immuno- 
fluorescence analysis in which test cells were 
incubated in buffer containing test plasma for 
30 min at 4°C and then, after washing, in 
buffer containing a saturating concentration 
of Auorescein-conjugated goat anti-mouse 
immunoglobulin (Tago, Inc., Burlingame, 
CA) for an additional 30 min at 4°C. Anti- 
body binding to test cells was quantitated by 
flow cytometry using selective gating of plate- 
lets (as determined by log forward angle 
versus log right angle light scatter) using a 
Coulter Epics C flow cytometer. The fluores- 
cence intensity of 5000 cells/determination 
was used as a quantitative measure of anti- 
body binding. 
Electron microscopy 
Segments of the left circumflex coronary 
artery were prepared for examination by 
scanning electron microscopy. The specimens 
were fixed for 24 h at 4°C in a solution of 
1 .O% glutaraldehyde (v/v) in 0.1 M cacodylate 
buffer (pH 7.4). The samples then were dehy- 
drated in a graded series of ethanol solutions, 
washed in hexamethyl dysilazane and desic- 
cated by critical point drying. The samples 
were sputter coated with 15 nm of gold spliced 
paladium (AuPd) and were examined with an 
AMR 1200 scanning electron microscope. 
Statistical analyses 
The data are expressed as the mean rf: S.E.M. 
Differences between groups were determined 
by Student’s t-test, when applicable, and were 
considered significant if P < 0.05. When indi- 
cated, hemodynamic parameters and platelet 
data were analyzed by two-factor repeated 
measures analysis of variance (ANOVA). If  a 
significant interaction was present, a Bonfer- 
roni multiple comparison method was used to 
determine the time period(s) at which the 
treatment means differed significantly 
(P < 0.05). I f  the time factor main effect was 
significant, a Newmann-Keuls multiple com- 
parison test was utilized to determine which 
means were significantly different. 
Results 
GTOUP characteristics 
Nineteen dogs were studied successfully in the 
electrical induction model of thrombotic coro- 
nary artery occlusion. The animals were 
assigned randomly to two treatment groups: 
vehicle control (normal saline, n = 13) or 
monoclonal platelet antibody 7E3 F(ab’), 
(n = 6). There was no difference in body 
weight between the two groups: control 
17.6 + 0.5 kg (mean f  s.E.M.) vs. antibody 
16.5 + 0.6 kg. There was no significant differ- 
ence in either the weight of the hearts deter- 
mined at post mortem (control 149 f  10 g vs. 
antibody 139 + 10 g) or the percentage of the 
total left ventricle subserved by the left cir- 
cumflex coronary artery (control 30.4 * 3.0% 
vs. antibody 31.4 f  4.5% j. The two groups 
did not differ with respect to their hemody- 
namic parameters which were recorded at the 
beginning of the experimental protocol (heart 
rate, blood pressure, coronary blood flow). 
Left circumjex coronary artery bloodjow and 
coronary artery thrombosis 
At the initiation of each experiment, left cir- 
cumflex coronary blood flow (CBF) did not 
differ significantly between the two groups: 
control 23.5 + 1.5 ml/min vs. antibody 
27.3 + 3.0 ml/min. Over the course of the 
experimental protocol, CBF was unchanged 
in the 7E3 antibody treated group and was at 
a mean value 21.5 + 3.1 ml/min when record- 
ed 5 h after initiation of the electrolytic lesion 
in the circumflex coronary artery (Table I). 
In the control group CBF decreased progres- 
sively over time, as a reflection of the intrava- 
scular thrombus which formed in each case. 
By the 5 h time point, each of the animals in 
the control group had developed an occlusive 
intracoronary thrombus and CBF was negligi- 
ble. The difference in CBF between the two 
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Baseline 97 f  4 119 f  7 160 f  6 175 f  9 24 k 2 27 k 3 
lh 100 f  5 117 * 7 160+5 164Ifl 7 18 k 2 25 k 4 
2h 99 + 6 120+ 7 158+ 7 166 * 9 8+3 25 f  3” 
3h 97 * 9 119& 10 170 + 20 164 f  8 8+5 24 f  3” 
4h 105 &- 2 115+ 7 175 + 20 167 + 10 13*9 23 + 4 
5h 90 118f8 165 163 +9 0 22 f  3 
Expressed as mean k standard error. ’ P < 0.001, compared to control at same time point. 
nvaluesforcontrol:baseline= 13: 1 h = 13:2h = 13;3h = 5;4h = 1. 
n values for 7E3 : 6 at all times. 
groups nearly achieved statistical significance 
at the end of the first hour of anodal current 
stimulation : control 17.5 + 2.4 ml/min vs. 
antibody 24.7 + 3.5 ml/min, P = 0.054. The 
difference in CBF between the two groups was 
significantly different at subsequent hourly 
recording: 2 h and 3 h. By 4 h and 5 h, the 
number of animals in the control was too few 
to allow for statistical analysis (P < 0.001 in 
each case). As the CBF diminished in the 
control group, there were spontaneous reac- 
tive hyperemic responses or oscillations where 
flow decreased to zero, then abruptly and 
spontaneously resumed at a rate higher than 
the preceding flow. The oscillations in the 
coronary flow did not occur in the antibody 
treated group (control 2.2 f  0.7 oscillations 
vs. antibody 0 + 0 oscillations, P < 0.05). 
The time to thrombosis in the control group 
was 136 f  15 min (n = 13) compared to the 
antibody group (n = 6) in which none of the 
vessels became occluded during the 300 min 
(5 h) observation period (P < 0.001). At the 
conclusion of each experiment, the left cir- 
cumflex coronary artery was opened longitu- 
dinally and, when present, the thrombus was 
recovered intact and weighed. The thrombus 
weight determined after 30 min of thrombotic 
occlusion in the control group was 8.8 f  1.3 
mg which was significantly larger than in the 
7E3 F(ab’)z antibody group, 2.2 + 1.1 mg 
(P < 0.001). In the control group thrombotic 
coronary artery occlusion developed in each 
animal, while in the antibody treated group 
small non-occlusive thrombi were found in 
three arteries, but all arteries were patent 
after 5 h of anodal current stimulation. It is 
noteworthy that the non-occlusive thrombi did 
not appear to disrupt or to diminish CBF. 
Thus, factors other than the presence of a 
small intravascular thrombi may interfere 
with coronary artery blood flow. 
Hemodynamic responses 
In both the control and 7E3 F(ab’), antibody 
treated groups, the main hemodynamic 
parameters (heart rate and blood pressure) 
remained essentially unchanged throughout 
the experimental period (Table 1). The heart 
rate and mean arterial blood pressure did not 
differ between the two groups when the 
number of control animals was large enough 
to allow for analysis. After the second hour of 
observation, there were progressively fewer 
animals remaining in the control group: 3 h 
(n = 2), 4 h (n = 2), and 5 h (n = 1). The 
rapid attrition within the control group was 
due to the fact that experiments were termin- 
ated 30 min after blood flow in the circumflex 
coronary artery had ceased as a result of an 
occlusive thrombus having formed in response 
to intimal injury. 
Platelet studies 
The circulating platelet counts did not change 
over time and did not differ significantly 
between the two groups at any time point in 
the experimental protocol, when the number 
of control animals was large enough to allow 
for comparison. The platelet counts in the 
control and treated group before adminis- 
tration of the antibody were: 453 + 47 x 103/ 
mm3 (n = 13) and 313 + 25 x 103/mm3 
(n = 6). One hour after administration of 
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FIGURE 2. (a) Platelet aggregation induced with 
ADP. Using two concentrations of ADP (2.5 /.I’M and 5.0 
PM), platelet aggregation was determined at three time 
points: baseline, 1 h and 5 h after treatment with diluent 
or the murine monoclonal 7E3 F(ab’), antibody. The cx 
uivo responsiveness of platelets to 2.5 PM ADP in those 
dogs that were subsequently randomized to antibody 
treatment was lower at baseline than the control platelets 
(§P < 0.05). However, the responsiveness of these same 
platelets to the higher concentration of ADP (5.0 PM) was 
similar to that of the platelets from control animals at 
baseline. Treatment with the monoclonal platelet anti- 
body 7E3 F(ab’)z significantly decreased platelet aggre- 
gation compare to baseline and the control group at 1 h 
(*P < 0.05). After 5 h, platelet antibody 7E3 F(ab’), sig- 
nificantly decreased platelet aggregation compared to 
baseline (*P < 0.05), however only one dog remained in 
the control group so this comparison could not be made. 
Data are mean + S.E.M. (b) Platelet aggregation induced 
with arachidonic acid. When two concentrations of ara- 
cbidonic acid (0.325 rnM and 0.65 mM) were used with 
epinephrine primed platelets (550 nM), aggregation was 
similar at baseline in the two treatment groups. Mono- 
clonal platelet antibody 7E3 F(ab’)* significantly 
decreased platelet aggregation compared to baseline and 
to the control group at 1 h (‘P < 0.001). After 5 h, plate- 
let antibody 7E3 F(ab’), significantly decreased platelet 
aggregation compared to baseline (*P < O.OOl), 
however, only one dog remained in the control group so 
this comparison could not be made. Data arc 
mean +- s.E.M. 
diluent or the 7E3 F(ab’)t antibody, the 
res 
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ective platelet counts were 397 If: 63 x 
10 /mm3 (n = 13) and 300 + 42 x 103/mm3 
(n = 6) (P = N.S.). After 5 h, the platelet 
count in the 7E3 F(ab’), antibody treated 
group was 37 1 + 63 x 103/mm3 (n = 6). 
One hour after vehicle administration in 
the control group there was no change from 
the baseline aggregation values [Fig. 2(a)]. 
After antibody treatment there was a signifi- 
cant decrease in platelet aggregation com- 
pared to baseline or to the control group at 1 
h, P < 0.05 for ADP, P < 0.001 for AA [Fig. 
2(b)]. After 5 h only one dog remained in the 
control group, so that statistical comparison 
between groups could not be performed. 
However, in the 7E3 F(ab’), antibody treat- 
ment group, significant inhibition of platelet 
aggregation was present when determined 5 h 
after administration of the antibody [Fig. 
2(a), (b)]. Zn uiuo platelet aggregation studies 
demonstrated that 7E3 F(ab’), was effective, 
in a concentration similar to that achieved in 
vi00 in preventing platelet aggregation 
induced by AA and collagen (Table 2). 
1 1 ‘Zndium labeled platelet studies 
Platelets were labeled successfully with 
“‘iridium and administered to each of six 
dogs which received 7E3 F(ab’)* antibody 
and to three dogs which served as controls. 
Each of the animals provided adequate data 
with respect to labeling efficiency and in viva 
radiolabel recovery. A significant decrease in 
platelet accumulation in the left circumflex 
coronary artery was observed in the group 
which was treated with 7E3 F(ab’)z antibody. 
When the left anterior descending and cir- 
cumflex coronary arteries from each dog were 
sectioned into proximal, middle, distal seg- 
ments, the ratios of radioactivity between the 
LCCA/LAD segments were much lower in the 
antibody treatment group when compared to 
the control group (Fig. 3). Platelets were able 
to adhere to the surface of the vessel wall to a 
limited extent in the 7E3 F(ab’), antibody 
treated group as evidenced from the presence 
of the radioactive counts. There was a signifi- 
cant inhibition of further accumulation of 
platelets by superimposition upon the adher- 
ent surface of thrombocytes, thereby imped- 
ing the full development of an occlusive 
thrombus. The l1 ‘indium labeled platelets 
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TABLE 2. In z&o platelet aggregation” 
7E3 F(ab’), antibody concentration @g/ml) 
Agonist 0 10 20 40 
Collagen 
1 : 10 38 f 6b 10 * 2 9*1 9fl 
1 : 80 45 + 3b 7.6 k 2 6.2 f  1 5.8 f  1 
Arachidonic acid 
0.650 mM 48 + 8b 7*2 4.8 f 2 6fl 
0.325 mM 57 + 3b 4+1 4.8 + 1 7.5 * 1 
’ Expressed as mean f  s.E.M.% light transmittance or % platelet aggregation. 
b *P < 0.05 for 0 rig/ml compared to each concentration of 7E3 F(ab’), for each 
agonist. 
n = 5 in each group. 
recovered in the few, non-occlusive, adherent 
thrombi that occurred in the antibody treat- 
ment group (225 + 146 ct/min/g, n = 6) sug- 
gests that there was a decrease in the number 
of platelets incorporated into the thrombotic 
material as assessed by the presence of the 
radiolabel as compared to the thrombus mass 
removed from each of the animals in the 
I T I 
” Proximal Middle Distal 
Coronary artery segment 
FIGURE 3. The presence of “‘iridium labeled plate- 
lets in the arterial proximal, middle and distal segments of 
the left anterior descending and left circumflex coronary 
artery. Homologous platelets were labeled with 
“tindium and reinjected before the administration of the 
7E3 antibody. Anodal current injury of the left circumflex 
coronary artery was induced in animals which served as 
vehicle controls (m) and in animals which received the 
7E3 F(ab’), antibody (0). Segments of the left anterior 
descending coronary artery (LAD) served as a reference. 
Three segments of each artery were weighed and gamma 
emission determined as ct/min/g of tissue. A ratio was cal- 
culated for purposes of comparison (LCCA/LAD). In the 
control dogs (n = 3), the ratios were higher than in the 
7E3 F(ab’), treated dogs (n = 6, *f’< 0.05 for each 
segment of artery). Of the three contiguous arterial seg- 
ments, the segment distal to the placement of the anodal 
stimulation electrode had the greatest incorporation of 
“‘iridium labeled platelets which coincided with the pre- 
sence and distribution of the thrombus within the vessel. 
control group (2 100 + 1200 ct/min/g, n = 3 ; 
P < 0.05). 
Analysis of plasma antibody concentrations 
Plasma from four dogs was analyzed before 
and at 1 h and 5 h after administration of 7E3 
Flab’), antibody. Flow cytometric analysis 
showed the linear mean intensity of test cells 
(5000 platelets) incubated with platelet poor 
plasma at baseline was 0.64 + 0.08 and 
increased to 1.03+0.11 at 1 h and 
12.03 + 0.33 at 5 h. There was a significant 
amount of excess antibody in the plasma over 
the time course of the experimental protocol 
with the administered dose of the 7E3 F(ab’), 
antibody. The slight increase at 5 h suggests 
the antibody may not be irreversibly bound to 
the platelets. The presence of antibody excess 
in the plasma assured that the antibody con- 
centration would not be limiting and that all 
available platelet glycoprotein GPIIb/IIIa 
receptors could be inhibited effectively by 
binding to the F(ab’) 2 . 
Electron microscopy 
The luminal surface of the left circumflex 
coronary artery near the site of insertion of the 
anodal stimulating electrode was examined by 
scanning electron microscopy. A scanning 
electron photomicrograph of a representative 
circumflex coronary artery, taken from a 
control animal, shows the presence of an 
occlusive thrombus mass within the vessel 
lumen comprised of platelet aggregates, eryth- 
rocytes and fibrinous material. The vessel was 
occluded completely by the thrombotic 
Antibody-induced Prevention of Coronary Artery Thrombosis 401 
FIGURE 4. A scanning electron photomicrograph of a LCCA from a control animal The region shown is the site at 
which the anodal stimulation electrode entered the vessel lumen. A view of the luminal surface of the left circumflrs 
coronary artery shows an organized, adherent thrombus within the vessel lumen composed of large aggregates of 
platelets and erythrocytes enmeshed in a fibrinous matrix. The thrombus is firmly attached to the underlying wsscl 
wall and overlies the point at which the anodal stimulation electrode enters the vessel lumen. 
material which is adherent at the site of vessel 
injury (Fig. 4). 
The ability of the 7E3 F(ab’), antibody to 
prevent platelet aggregation and subsequent 
thrombus development on the damaged endo- 
thelium is illustrated in Figure 5 which shows 
relatively few clusters of platelets adherent in 
the area of the disrupted endothelium with 
minimal fibrinous material present in the 
denuded area. Despite the thrombogenic 
potential of the injured intimal surface, 
occlusive thrombus formation did not occur in 
the presence of the 7E3 F(ab’)z antibody. 
Discussion 
The experimental model of coronary artery 
thrombosis 
The canine model employed in this study pos- 
sesses anatomic features of coronary artery 
thrombosis in which an occlusive vascular 
lesion develops in response to vessel wall 
intimal injury in a region of high-grade sten- 
osis. The application of an anodal current to 
the intimal surface of the coronary artery has 
been shown to be a reliable means of produc- 
ing a thrombogenic substrate upon which 
platelets and blood clotting factors will inter- 
act and result in the formation of a thrombus 
mass (Romson et al. 1980a, b, 1982). The 
importance of an in uivo model of coronary 
artery thrombosis becomes apparent in light 
of the increasing body of data demonstrating 
that thrombi are composed of platelets and 
fibrin and that inhibition of the platelet 
GPIIb/IIIa receptor can prevent platelet . 1 
aggregation m uzvo as well as ex vivo. The 
experimental model of intracoronary artery 
thrombosis, as developed in this laboratory 
(Romson et al., 1980b), presents a precisely 
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FIGURE 5. A scanning electron photomicrograph of a LCXA f ram a 7E3 Fjah’), treated animal. The region shown 
is the site at which the anodal stimulation electrode entered the vessel lumen. There is an absence of thromhoric 
material at the site despite the presence of endothclial damage. The endothelium which is denuded remains frer of large 
platelet aggregates and fibrinok material. 
defined electrolytic injury resulting in endo- 
thelial cell damage in a region of high-grade 
stenosis. The resulting anatomic substrate 
provides an in viva environment which will 
lead to the initiation of cell-cell interactions 
(platelet-endothelial cell) associated with 
intravascular thrombus formation. 
Selection of the 7E3 F(ab’) z monoclonal antibody 
Injury to the surface of the blood vessel 
exposes components of the arterial media of 
which fibrillar collagen along with other 
locally released mediators induce platelet 
adhesion. Platelet aggregation is superim- 
posed upon the adherent layer of platelets as a 
result of at least three known mechanisms: 
metabolites of arachidonic acid, the release of 
adenosine diphosphate, and/or the pathway 
involving collagen and thrombin. Each of 
these pathways may trigger the expression of 
the platelet receptor GPIIb/IIIa complex. 
The surface expression of the GPIIb/IIIa 
receptor complex leads to a binding of fibrino- 
gen, and other adhesive glycoproteins (van 
Willebrand factor, fibrinogen, fibronectin), to 
or near the GPIIb/IIIa receptor complex. 
Platelet aggregation induced by adenosine 
diphosphate, collagen, epinephrine and 
thrombin is dependent on the binding of 
fibrinogen or other ligands to the GPIIb/IIIa 
receptor complex (Coller et al., 1983). The 
latter has been identified tentatively as the 
fibrinogen receptor. 
The dimeric structure of fibrinogen allows 
it to interact simultaneously through the 
GPIIb/IIIa receptor complex with two plate- 
lets thereby serving as a bridging molecule. 
Caller and colleagues (Caller et al., 1983; 
Coller, 1985; Caller and Scudder, 1985 ; 
Sakariassen et al., 1986) have developed 
murine monoclonal antibodies which can 
prevent the binding of fibrinogen to the plate- 
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let glycoprotein IIb/IIIa receptor complex. 
Antibody induced inhibition of the GPIIb/ 
IIIa receptor complex has been demonstrated 
to block the subsequent binding of fibrinogen 
when platelets are activated (Coller et al., 
1983; Hanson et al., 1988). The F(ab’), frag- 
ment which is devoid of the Fc portion of the 
immunoglobulin molecule, rather than the 
intact antibody, was employed in the present 
study in an attempt to circumvent the induc- 
tion of thrombocytopenia secondary to 
recognition of the Fc portion of the murine 
monoclonal antibody by the phagocytic cells 
of the animal’s reticuloendothelial system. 
The F(ab’), fragment would have less of a 
tendency to be cleared by splenic macro- 
phages thereby providing a plasma excess of 
antibody to interact with available platelet 
receptor complexes. The continued presence 
of t1 ‘iridium labeling in the residual 
thrombus mass as well as in the circulating 
pool of platelets throughout the duration of 
the experimental protocol demonstrates that 
the platelets which bound to the antibody are 
not removerd prematurely from the circula- 
tion. 
Administration of the 7E3 F(ab’), antibody 
was not associated with significant changes in 
the circulating platelet count. A similar obser- 
vation has been reported by others who have 
employed the same monoclonal antibody in 
the canine (Coller and &udder, 1985 ; Coller 
et al., 1985). The antibody has been demon- 
strated to have a high specificity for platelets 
and megakaryocytes, thus restricting its effect 
to these cells (Coller et al., 1983) and to cross 
react with the GPIIb/IIIa receptor on plate- 
lets of primates and dogs (Coller et al., 1986). 
Nevertheless, the specific inhibition of the 
GPIIb/IIIa glycoprotein was not associated 
with evidence of excessive bleeding from the 
site of the operative incision. The antibody, 
while interfering with platelet-platelet inter- 
actions through the inhibition of fibrinogen 
binding, may not alter other platelet depen- 
dent mechanisms associated with hemostasis. 
Thf presence of non-occlusive thrombi 
attached to the site of intimal injury in the 
7E3 F(ab’), antibody treated animals would 
be consistent with the notion that platelet 
adhesion may not be limited entirely. The 
presence of antibody excess in the plasma 
would rule out the possibility that a small 
number of residual unblocked GPIIa/IIIb 
receptor complexes may have remained func- 
tional and would have contributed to the 
facilitation of hemostasis. Thus other mecha- 
nisms such as GPIb and its interaction with 
von Willebrand factor in the subendothelium 
might still function so as to promote a limited 
degree of platelet adhesion. The failure of the 
platelet GPIIb/IIIa monoclonal antibody to 
promote excessive bleeding has been reported 
by other investigators (Coller et al., 1986) and 
may be related to the presence of alternate 
receptor sites which can continue to partici- 
pate in platelet adhesion to the sub- 
endothelium. 
The prevention of intravascular thrombosis in 
response to endothelial cell injyv 
We undertook the present investigation in an 
effort to define the role of the platelet fibrino- 
gen receptor in thrombus formation in vivo 
and to determine if selective inhibition of the 
GPIIb/IIIa platelet receptor complex with 
the 7E3 F(ab’), antibody could prevent the 
development of occlusive coronary artery 
thrombosis and the incorporation of platelets 
into the resulting thrombus mass. Treatment 
with a monoclonal platelet antibody, 7E3 
F(ab’),(0.8 mg/kg), was effective in prevent- 
ing occlusive thrombus formation. As a result, 
the left circumflex coronary artery blood flow 
remained stable over the duration of the 
experimental period. The 7E3 F(ab’), anti- 
body has been shown to be an effective anti- 
thrombotic agent in the Folts’ model of 
cyclical blood flow reduction in the canine 
coronary artery and in monkey carotid 
arteries (Coller et al., 1986). In both of these 
models the platelet is thought to interact with 
damaged vascular endothelium in an area of 
critical stenosis, adhering and aggregating to 
form an obstructing thrombus. It is possible 
that activated platelets release vasospastic 
substances that cause changes in coronary 
vascular tone so that obstruction of the vascu- 
lar lumen could occur with a smaller 
thrombus mass than would be expected in the 
absence of an obstructive lesion. Inhibition of 
arachidonic acid induced aggregation with 
7E3 F(ab’), antibody could not be overcome 
with epinephrine in vitro. The oscillatory coro- 
nary flow pattern which characterizes the 
Folts’ model of coronary thrombosis is 
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enhanced by the systemic infusion of epi- 
nephrine. The inhibition of flow reductions by 
the 7E3 F(ab’), fragment of antibody 7E3, 
however, was not reversed by epinephrine 
(Coller et al., 1986). Gold and associates 
(1988) have demonstrated that the 7E3 
F(aW 2 monoclonal antibody accelerated 
thrombolysis with recombinant tissue plas- 
minogen activator and prevented reocclusion 
in a canine model in which coronary throm- 
bosis was induced by the injection of stored 
blood and thrombin directly into the coro- 
nary artery. The induced coronary artery 
thrombi in the control animals underwent 
lysis with tissue plasminogen activator, but in 
each instance reoccluded. Thus, as in our 
studies with 7E3 F(ab’), antibody, intrava- 
scular platelet aggregation could be prevented 
by selective inhibition of the GPIIb/IIIa 
receptor. 
The 7E3 monoclonal platelet antibody did 
not exhibit significant hemodynamic effects as 
suggested by the failure to alter heart rate and 
blood pressure. In both groups the platelet 
count was not affected by the experimental 
protocol. The use of the murine monoclonal 
7E3 F(ab’) z fragments did not result in a 
reduction in the circulating platelet count. A 
similar benign response to the F(ab’), frag- 
ments has been confirmed in several other 
models using various animal species (Coller et 
al., 1986; Gold et al., 1988; Hanson et al., 
1988). Coincident with the presence of the 
7E3 F(ab’), on the GPIIb/IIIa receptor is the 
observation that the ex V&JO inhibition of ADP 
or arachidonic acid induced platelet aggre- 
gation persisted for 5 h after the antibody had 
been administered. Others have observed 
even longer inhibition of platelet aggregation, 
up to 48 h, with minimal bleeding com- 
plications. (Hanson et al., 1988). 
The “‘iridium labeled platelets which sub- 
sequently were exposed to antibody did not 
adhere to the coronary vascular endothelium 
to the same degree as was observed to occur in 
the control group of animals. Several methods 
of vascular injury, including electrically 
induced deep venous thrombosis and endo- 
thelial denudation of the femoral and carotid 
artery of the dog, are known to cause accumu- 
lation of platelets detectable by il’indium 
labeling (Thakur et al., 1976). The radio- 
activity ratios in the coronary arterial seg- 
ments were less in the vessel specimens 
obtained from antibody treated dogs, thereby 
suggesting that fewer platelets had adhered to 
the vessel wall at the site of intimal injury. 
The resulting thrombus was decreased signifi- 
cantly in overall mass. The ultimate thrombus 
mass was smaller in the presence of 7E3 
F(ab’), and the concentration of the radiola- 
be1 was less in the thrombi recovered from the 
vessels of animals which received antibody. 
Because fewer platelets are present, the accu- 
mulated mass necessary to obstruct the vessel 
or the amount of mediators released to evoke 
the other components of the thrombus (fibrin 
and neutrophils) are not present. A decrease 
in the number of platelets incorporated into 
the thrombus mass might also be associated 
with a decrease in the local production of 
fibrinolytic inhibitors which would delay the 
process of fibrinolysis (24). The development 
of smaller thrombi may result from retarding 
or inhibiting those events which lead to plate- 
let accretion on the surface of the thrombus 
while at the same time permitting unopposed 
expression of endogenous fibrinolytic mecha- 
nisms. It is uncertain whether the local 
decrease in the number of accumulated plate- 
lets and/or the inhibition of aggregation and 
mediator release account for the observed sta- 
bilization of the coronary blood flow in the 
presence of a nonocclusive thrombus. 
Conclusions 
The intravenous administration of the murine 
monoclonal 7E3 F(ab’)z platelet antibody did 
not produce any adverse effects upon the 
recorded cardiovascular parameters as evi- 
denced by a failure to alter heart rate, blood 
pressure, or coronary artery blood flow. In 
addition the circulating platelet count was 
unaltered and bleeding or excessive blood loss 
was not a complication. Whereas the anti- 
body did not achieve a complete prevention of 
thrombus formation, it did result in a signifi- 
cant decrease in the ultimate size of the 
thrombus mass thereby preserving coronary 
artery blood flow. 
The 7E3 F(ab’), platelet antibody may 
alter the rate of incorporation of functionally 
intact platelets into the thrombus mass which 
forms in response to intimal injury in the coro- 
nary artery. The latter would result in a 
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favorable shift in the equilibrium between 
those factors which promote intravascular 
thrombus formation and the endogenous local 
events which favor thrombolysis. Whether or 
not the immunogenicity of murine mono- 
clonal antibody will preclude its clinical 
application must be determined. Based upon 
these observations, it might be speculated that 
the 7E3 F(ab’), antibody may serve as an 
adjunct to other measures directed against 
intravascular thrombus formation, particu- 
larly those associated with coronary artery 
occlusion after percutaneous transluminal 
coronary angioplasty or reocclusion after suc- 
cessful thrombolysis as has been suggested by 
recent experimental studies (Coller et a/., 
1986; Gold etal., 1988). 
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